# OnCo record nct05585320 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05585320/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05585320", "NCT05585320" ;
  schema:name "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Dabrafenib, Pembrolizumab in melanoma and non-small-cell lung cancer, run by Immuneering Corporation, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05585320/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05585320> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-10-31" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/immuneering/> .